Design Therapeutics Inc

DSGN

Add to Watchlist

14.370USD

-0.170-1.17%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Design Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

125 / 382

Overall Ranking

251 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Design Therapeutics Inc Highlights

StrengthsRisks

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Undervalued

The company’s latest PE is -12.05, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.66M shares, increasing 1.75% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 287.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.55.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

17.167

Target Price

+18.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Design Therapeutics Inc is 5.46, ranking 351 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Design Therapeutics Inc is 6.81, ranking 206 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.05, which is -87.24% below the recent high of -1.54 and -9.88% above the recent low of -13.24.

Score

Industry at a Glance

Previous score

6.81

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Design Therapeutics Inc is 9.00, ranking 17 out of 382 in the Biotechnology & Medical Research industry. The average price target is 12.50, with a high of 15.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Design Therapeutics Inc is 7.56, ranking 57 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.10 and the support level at 11.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.59

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Design Therapeutics Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.89%, representing a quarter-over-quarter decrease of 8.26%. The largest institutional shareholder is Steven Cohen, holding a total of 5.37M shares, representing 8.60% of shares outstanding, with 168.60% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ansari (Aseem Z. Ph.D.)

7.67M

--

SR One Capital Management, LP

6.53M

--

Point72 Asset Management, L.P.

Star Investors

5.37M

+60.81%

Light Irrevocable Trust.

3.83M

--

Star Irrevocable Trust.

3.83M

--

Quan Venture Fund II LP

4.00M

-3.22%

Logos Global Management LP

2.50M

--

Baker Bros. Advisors LP

2.23M

+30.37%

BlackRock Institutional Trust Company, N.A.

1.86M

+4.57%

Vivo Capital, LLC

1.61M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Design Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 1.74. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Design Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Design Therapeutics Inc

DSGN

6.20 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment